We are live on ! Find out more
ARTL icon

Artelo Biosciences
ARTL

5 hedge funds and large institutions have $338K invested in Artelo Biosciences in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.65% less ownership

Funds ownership: 4.74% → 4.09% (-0.65%)

17% less funds holding

Funds holding: 6 → 5 (-1)

27% less capital invested

Capital invested by funds: $464K → $338K (-$126K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
5
Holders Change
-1
Holders Change %
-16.67%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$3.75K
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$2.82K
3
TRCT
Tower Research Capital (TRC)
New York
+$939

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
-$37K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$24.9K
3
UBS Group
UBS Group
Switzerland
-$2.82K

ARTL Hedge Fund Activity: Q4 2022 in Review

5 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q4 2022, worth a combined $338K — down 27% from $464K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of ARTL and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.

The largest buyer was Geode Capital Management, adding an estimated $3.75K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $37K sold.

  • 5 institutional investors held Artelo Biosciences (ARTL) as of Q4 2022, down from 6 in Q3 2022.
  • Funds reported $338K of Artelo Biosciences stock for Q4 2022, down 27% quarter-over-quarter.
  • 0 funds opened new Artelo Biosciences positions in Q4 2022 and 1 closed out, a net change of -1 holder.
  • The largest Artelo Biosciences buyer in Q4 2022 was Geode Capital Management, an estimated $3.75K added.
  • The largest Artelo Biosciences seller in Q4 2022 was Two Sigma Investments, an estimated $37K sold.

Based on aggregated 13F filings for Q4 2022.